Search research articles
Contact Us
Filters
Showing results (101-110 of 224) with videos related to
Page
of 23
Sort By:
Clinical Lymphoma, Myeloma & Leukemia
|
June 7, 2025
Feasibility of Bruton's Tyrosine Kinase Inhibitor Discontinuation in Chronic Lymphocytic Leukemia: The Patient Perspective
Deborah M Stephens, Chris Stewart, Liza Avruch, et al.
Haematologica
|
September 14, 2023
Ultra-deep mutational landscape in chronic lymphocytic leukemia uncovers dynamics of resistance to targeted therapies
David W Woolston, Nathan D Lee, Mazyar Shadman, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
January 9, 2024
Mosunetuzumab Safety Profile in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma: Clinical Management Experience From a Pivotal Phase I/II Trial
Matthew Matasar, Nancy L Bartlett, Mazyar Shadman, et al.
Journal of Cellular and Molecular Medicine
|
December 1, 2022
Predictors of response to axicabtagene-ciloleucel CAR T cells in aggressive B cell lymphomas: A real-world study
Lorenzo Iovino, Qian Vicky Wu, Jenna Voutsinas, et al.
Leukemia & Lymphoma
|
July 11, 2022
Predictors of cytopenias after treatment with axicabtagene ciloleucel in patients with large B-cell lymphoma
Lorena Panaite, Qian Vicky Wu, Jenna Voutsinas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 31, 2025
Zanubrutinib and Venetoclax for Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma With and Without Del(17p)/<i>TP53</i> Mutation: SEQUOIA Arm D Results
Mazyar Shadman, Talha Munir, Shuo Ma, et al.
Blood Advances
|
November 17, 2022
Efficacy, safety, and molecular response predictors of oral ixazomib and short-course rituximab in untreated iNHL
Solomon A Graf, Ryan C Lynch, Chaitra S Ujjani, et al.
Leukemia & Lymphoma
|
October 1, 2024
Real-world outcomes following ibrutinib dose reduction in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma
Mazyar Shadman, Monika Salkar, Bhavini Srivastava, et al.
Haematologica
|
September 5, 2024
Outcomes of patients with primary central nervous system lymphoma following CD19-targeted chimeric antigen receptor T-cell therapy
Santiago Mercadal, Kwang Woo Ahn, Mariam Allbee-Johnson, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
November 5, 2023
Pembrolizumab With R-CHOP in Previously Untreated DLBCL: Sustained, High Efficacy, and Safety With Long-Term Follow-Up
Carrie Ho, Ajay K Gopal, Brian G Till, et al.
Page
of 23
Search research articles
Search
Showing results (101-110 of 224) with videos related to
Sort By:
Page
of 23
Clinical Lymphoma, Myeloma & Leukemia
|
June 7, 2025
Feasibility of Bruton's Tyrosine Kinase Inhibitor Discontinuation in Chronic Lymphocytic Leukemia: The Patient Perspective
Deborah M Stephens, Chris Stewart, Liza Avruch, et al.
Haematologica
|
September 14, 2023
Ultra-deep mutational landscape in chronic lymphocytic leukemia uncovers dynamics of resistance to targeted therapies
David W Woolston, Nathan D Lee, Mazyar Shadman, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
January 9, 2024
Mosunetuzumab Safety Profile in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma: Clinical Management Experience From a Pivotal Phase I/II Trial
Matthew Matasar, Nancy L Bartlett, Mazyar Shadman, et al.
Journal of Cellular and Molecular Medicine
|
December 1, 2022
Predictors of response to axicabtagene-ciloleucel CAR T cells in aggressive B cell lymphomas: A real-world study
Lorenzo Iovino, Qian Vicky Wu, Jenna Voutsinas, et al.
Leukemia & Lymphoma
|
July 11, 2022
Predictors of cytopenias after treatment with axicabtagene ciloleucel in patients with large B-cell lymphoma
Lorena Panaite, Qian Vicky Wu, Jenna Voutsinas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 31, 2025
Zanubrutinib and Venetoclax for Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma With and Without Del(17p)/<i>TP53</i> Mutation: SEQUOIA Arm D Results
Mazyar Shadman, Talha Munir, Shuo Ma, et al.
Blood Advances
|
November 17, 2022
Efficacy, safety, and molecular response predictors of oral ixazomib and short-course rituximab in untreated iNHL
Solomon A Graf, Ryan C Lynch, Chaitra S Ujjani, et al.
Leukemia & Lymphoma
|
October 1, 2024
Real-world outcomes following ibrutinib dose reduction in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma
Mazyar Shadman, Monika Salkar, Bhavini Srivastava, et al.
Haematologica
|
September 5, 2024
Outcomes of patients with primary central nervous system lymphoma following CD19-targeted chimeric antigen receptor T-cell therapy
Santiago Mercadal, Kwang Woo Ahn, Mariam Allbee-Johnson, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
November 5, 2023
Pembrolizumab With R-CHOP in Previously Untreated DLBCL: Sustained, High Efficacy, and Safety With Long-Term Follow-Up
Carrie Ho, Ajay K Gopal, Brian G Till, et al.
Page
of 23